What is Cystografin and how is it used?
Cystografin is a prescription medicine used as a contrast agent for Retrograde Cystourethrography. Cystografin may be used alone or with other medications.
Cystografin belongs to a class of drugs called Iodinated Contrast Media; Contrast Media, Ionic/High Osmolality.
What are the possible side effects of Cystografin?
Cystografin may cause serious side effects including:
- difficulty breathing,
- swelling of your face, lips, tongue, or throat, and
Get medical help right away, if you have any of the symptoms listed above.
The most common side effects of Cystografin include:
- injection site reactions,
- changes in taste, and
- widening of blood vessels
Tell the doctor if you have any side effect that bothers you or that does not go away.
These are not all the possible side effects of Cystografin. For more information, ask your doctor or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Cystografin is a radiopaque contrast agent supplied as a sterile, clear, colorless to pale yellow, mobile or slightly viscous solution. Each mL provides 300 mg diatrizoate meglumine with 0.4 mg edetate disodium as a sequestering agent. Each mL of solution also contains approximately 141 mg organically bound iodine. At the time of manufacture, the air in the container is replaced by nitrogen. The preparation should be protected from strong light.
Cystografin is indicated for retrograde cystourethrography.
DOSAGE AND ADMINISTRATION
Preparation of the Patient
Appropriate preparation is desirable for optimal results. A laxative the night before the examination and a low residue diet the day before the procedure are recommended.
The dose for retrograde use in cystography and voiding cystourethrography ranges from 25 to 300 mL depending on the age of the patient and the degree of bladder irritability; amounts greater than 300 mL may be used if the bladder capacity allows. Best results are obtained when the bladder is filled with the contrast agent. If desired, the preparation may be diluted with sterile water or sterile saline as indicated in the table below.
After sterile catheterization, the bladder should be filled to capacity with Cystografin using a suitable sterile administration set. Care should be taken to avoid using excessive pressure. The presence of bladder discomfort or reflux and/or spontaneous voiding usually indicates that the bladder is full.
The commonly employed radiographic techniques should be used. A scout film is recommended before the contrast agent is administered.
USE DILUTED SOLUTIONS IMMEDIATELY
|100 mL Bottle|
Sterile Water or Sterile Saline Added
|% Diatrizoate Meglumine w/v||% Organically Bound Iodine w/v||Total Volume|
|0 mL||30.0||14.1||100 mL|
|25 mL||24.0||11.3||125 mL|
|50 mL||20.0||9.4||150 mL|
|67 mL||18.0||8.5||167 mL|
|300 mL Bottle|
Sterile Water or Sterile Saline Added
|0 mL||30.0||14.1||300 mL|
|50 mL||25.7||12.1||350 mL|
Cystografin (Diatrizoate Meglumine Injection USP 30%) is available in 200 mL and 400 mL bottles containing 100 mL and 300 mL of Cystografin respectively with sufficient capacity for dilution up to 167 mL and 350 mL respectively.
Store at 20-25°C (68-77°F) [See USP]. Protect from light.
Cystografin Dilute (Diatrizoate Meglumine Injection USP 18%) is also available, as a 300 mL fill in a 400 mL bottle.
Manufactured for: Bracco Diagnostics Inc., Monroe Township, NJ 08831, by Patheon Italia S.p.A. 03013 Ferentino (Italy). Revised: Apr 2018
If intravasation of this drug occurs, the reactions which may be associated with intravenous administration may possibly be encountered. Hypersensitivity or anaphylactoid reactions may occur. Severe reactions may be manifested by edema of the face and glottis, respiratory distress, convulsions or shock; such reactions may prove fatal unless promptly controlled by such emergency measures as maintenance of a clear airway and immediate use of oxygen and resuscitative drugs.
Thyroid function tests indicative of hypothyroidism or transient thyroid suppression have been uncommonly reported following iodinated contrast media administration to adult and pediatric patients, including infants. Some patients were treated for hypothyroidism.
No information provided.
Severe sensitivity reactions are more likely to occur in patients with a personal or family history of bronchial asthma, significant allergies, or previous reactions to contrast agents.
A history of sensitivity to iodine per se or to other contrast agents is not an absolute contraindication to the use of diatrizoate meglumine, but calls for extreme caution in administration.
Safe and effective use of this preparation depends upon proper dosage, correct technique, adequate precautions, and readiness for emergencies.
Retrograde cystourethrography should be performed with caution in patients with a known active infectious process of the urinary tract.
Contrast agents may interfere with some chemical determinations made on urine specimens; therefore, urine should be collected before administration of the
contrast medium or two or more days afterwards.
Use In Specific Populations
Animal reproduction studies have not been conducted with diatrizoate meglumine injection. It is also not known whether diatrizoate meglumine injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Cystografin should be administered to a pregnant woman only if clearly needed.
Drugs and Treatment Resources
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Health Solutions From Our Sponsors